Results 311 to 318 of about 28,689 (318)
Some of the next articles are maybe not open access.

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

New England Journal of Medicine, 2012
Claire N Harrison   +2 more
exaly  

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

Leukemia, 2020
exaly  

Ruxolitinib‐associated infections: A systematic review and meta‐analysis

American Journal of Hematology, 2018
Federico Lussana   +2 more
exaly  

Synthesis of (R)-Ruxolitinib

Synfacts, 2015
openaire   +2 more sources

Ruxolitinib treatment for myelofibrosis

Community Oncology, 2012
openaire   +2 more sources

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

Leukemia, 2016
exaly  

Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib

Frontiers in Oncology, 2019
Elena Rossi   +2 more
exaly  

Ruxolitinib REACHes FOR children with GVHD

Blood
openaire   +2 more sources
myelofibrosis
medicine
bone marrow
internal medicine
oncology
gastroenterology
polycythemia vera
clinical trial
biology
previous   30  31  32  

Home - About - Disclaimer - Privacy